August is normally quiet in Washington, DC, but in keeping with the theme of 2020, this month has been more frenetic. While we beat back new taxes on the insights industry, the Insights Association has had to tangle with the demise of the U.S.-EU Privacy Shield for data transfer, further pandemic relief, some new threats to pharma MR, the finalization of CCPA, and an attempt to rush the 2020 Census that threatens the statistical viability of most marketing research and data analytics in the U.S.
Maine Finalizes Pharmaceutical Regulations, Clarifying the Legality of Research Respondent Incentives for Physicians
In finalizing Maine’s ban on pharmaceutical manufacturer gifts to health care practitioners, the Maine Board of Pharmacy responded to the Insights Association that it should not restrict respondent incentives for participation in bona fide marketing research.
Adverse event reporting, with which some pharmaceutical and medical device manufacturers require assistance from their marketing research and data analytics departments and partners/vendors, continues during the COVID-19 crisis.
The Insights Association has scored several policy victories in recent months – on Capitol Hill and in states across the U.S. Here are some of the highlights with content links for you and your team, all made possible by your membership.
A look back, counting down the Insights Association's top seven advocacy wins from the last decade that helped our marketing research and data analytics industry members create competitive advantage.
A (data) gathering storm? An update on legislation and regulation impacting the insights industry in 2019
Insights Association lobbyist Howard Fienberg provides a 2019 update on legislation and regulation impacting the marketing research and data analytics industry for Quirks magazine.
Each time the state of Minnesota has tried to clarify treatment of respondent incentives for the participation of health care practitioners in marketing research sponsored by pharmaceutical manufacturers, companies still end up confused. What do the law, regulations and guidance tell us?
Philadelphia Rejects Bill That Would Have Banned Pharmaceutical Marketing Research with Healthcare Professionals
Legislation in the city of Philadelphia that would have cut off pharmaceutical marketing research with doctors was defeated in the city council yesterday.
The Insights Association contributes to Pharma Market Research Report 14th Annual Predictions Issue